These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. Gabizon A; Shiota R; Papahadjopoulos D J Natl Cancer Inst; 1989 Oct; 81(19):1484-8. PubMed ID: 2778836 [TBL] [Abstract][Full Text] [Related]
6. Application of liposomes for development of oral vaccines: study of in vitro stability of liposomes and antibody response to antigen associated with liposomes after oral immunization. Han M; Watarai S; Kobayashi K; Yasuda T J Vet Med Sci; 1997 Dec; 59(12):1109-14. PubMed ID: 9450240 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Huang SK; Mayhew E; Gilani S; Lasic DD; Martin FJ; Papahadjopoulos D Cancer Res; 1992 Dec; 52(24):6774-81. PubMed ID: 1458465 [TBL] [Abstract][Full Text] [Related]
8. Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Dos Santos N; Mayer LD; Abraham SA; Gallagher RC; Cox KA; Tardi PG; Bally MB Biochim Biophys Acta; 2002 Apr; 1561(2):188-201. PubMed ID: 11997119 [TBL] [Abstract][Full Text] [Related]
9. Effect of matrix lipid chain length on liposomes containing cholesterol and ganglioside GM1: implications in drug delivery. Bedu-Addo FK; Huang L J Pharm Sci; 1996 Jul; 85(7):714-9. PubMed ID: 8818995 [TBL] [Abstract][Full Text] [Related]
10. Large liposomes containing ganglioside GM1 accumulate effectively in spleen. Liu D; Mori A; Huang L Biochim Biophys Acta; 1991 Jul; 1066(2):159-65. PubMed ID: 1854781 [TBL] [Abstract][Full Text] [Related]
11. The presence of GM1 in liposomes with entrapped doxorubicin does not prevent RES blockade. Parr MJ; Bally MB; Cullis PR Biochim Biophys Acta; 1993 Jun; 1168(2):249-52. PubMed ID: 8504161 [TBL] [Abstract][Full Text] [Related]
12. In vivo evaluation of doxorubicin carried with long circulating and remote loading proliposome. Junping W; Maitani Y; Takayama K; Nagai T Int J Pharm; 2000 Aug; 203(1-2):61-9. PubMed ID: 10967428 [TBL] [Abstract][Full Text] [Related]
13. In vivo antitumor activity of cis-bis-neodecanoato-trans-R,R-1, 2-diaminocyclohexane platinum(II) formulated in long-circulating liposomes. Mori A; Wu SP; Han I; Khokhar AR; Perez-Soler R; Huang L Cancer Chemother Pharmacol; 1996; 37(5):435-44. PubMed ID: 8599866 [TBL] [Abstract][Full Text] [Related]
14. Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx Burade V; Bhowmick S; Maiti K; Zalawadia R; Jain D; Rajamannar T Cancer Chemother Pharmacol; 2017 May; 79(5):899-913. PubMed ID: 28349166 [TBL] [Abstract][Full Text] [Related]
15. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. Ishida T; Atobe K; Wang X; Kiwada H J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355 [TBL] [Abstract][Full Text] [Related]
16. Kinetic analysis of tissue distribution of doxorubicin incorporated in liposomes in rats (II). Harashima H; Midori Y; Ohshima S; Yachi K; Kikuchi H; Kiwada H Biopharm Drug Dispos; 1993 Oct; 14(7):595-608. PubMed ID: 8251614 [TBL] [Abstract][Full Text] [Related]
17. In vivo trafficking of long-circulating liposomes in tumour-bearing mice determined by positron emission tomography. Oku N; Tokudome Y; Tsukada H; Kosugi T; Namba Y; Okada S Biopharm Drug Dispos; 1996 Jul; 17(5):435-41. PubMed ID: 8830978 [TBL] [Abstract][Full Text] [Related]
18. Investigation of the antitumor activity and toxicity of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in a murine breast cancer animal model. Franco MS; Roque MC; de Barros ALB; de Oliveira Silva J; Cassali GD; Oliveira MC Biomed Pharmacother; 2019 Jan; 109():1728-1739. PubMed ID: 30551427 [TBL] [Abstract][Full Text] [Related]
19. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Charrois GJ; Allen TM Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619 [TBL] [Abstract][Full Text] [Related]
20. A comparative study on the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the Lou/M Wsl rat. Storm G; van Hoesel QG; de Groot G; Kop W; Steerenberg PA; Hillen FC Cancer Chemother Pharmacol; 1989; 24(6):341-8. PubMed ID: 2791187 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]